ABBVD Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 5/6 |
AbbVie Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$17.90 |
52 Week High | US$20.00 |
52 Week Low | US$13.00 |
Beta | 0.56 |
1 Month Change | -8.67% |
3 Month Change | -1.11% |
1 Year Change | 5.60% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 50.42% |
Recent News & Updates
Recent updates
Shareholder Returns
ABBVD | AR Biotechs | AR Market | |
---|---|---|---|
7D | 1.1% | 0% | 0% |
1Y | 5.6% | 0% | 0% |
Return vs Industry: ABBVD exceeded the AR Biotechs industry which returned -9% over the past year.
Return vs Market: ABBVD underperformed the AR Market which returned 295.5% over the past year.
Price Volatility
ABBVD volatility | |
---|---|
ABBVD Average Weekly Movement | 6.1% |
Biotechs Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in AR Market | 0% |
10% least volatile stocks in AR Market | 0% |
Stable Share Price: ABBVD has not had significant price volatility in the past 3 months.
Volatility Over Time: ABBVD's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 50,000 | Rick Gonzalez | www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
ABBVD fundamental statistics | |
---|---|
Market cap | US$297.27b |
Earnings (TTM) | US$4.82b |
Revenue (TTM) | US$54.32b |
62.3x
P/E Ratio5.5x
P/S RatioIs ABBVD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ABBVD income statement (TTM) | |
---|---|
Revenue | US$54.32b |
Cost of Revenue | US$16.73b |
Gross Profit | US$37.59b |
Other Expenses | US$32.77b |
Earnings | US$4.82b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
Earnings per share (EPS) | 2.72 |
Gross Margin | 69.21% |
Net Profit Margin | 8.87% |
Debt/Equity Ratio | 573.6% |
How did ABBVD perform over the long term?
See historical performance and comparison